PDF(Sci-hub)
Abstract：
UNASSIGNED: Endovascular aortic repair (EVAR) is obviously less invasive than open aortic repair (OAR) for the treatment of infra-renal abdominal aortic aneurysm (AAA). However, it is not free of complications which can potentially result in severe morbidity or even mortality. The purpose of this study was to share our single-center experience with stent-graft related and systemic complications associated with EVAR.
UNASSIGNED: Patients with infra-renal AAA treated by elective and emergency EVAR between March 2014 and November 2020 were retrospectively identified. Demographic data, risk factors, American Society of Anesthesiologists (ASA) score, systemic complications, stent-graft related complications, surgical site complications, 30-day mortality, late EVAR related mortality, estimated blood loss, intensive care unit (ICU) length of stay (LOS), hospital LOS and follow-up durations were collected and analyzed.
UNASSIGNED: A total of 43 patients underwent EVAR during the period of study. There were 42 males (97.7%) and 1 female (2.3%). The mean age was 68.8 ± 6.2 years. Elective EVAR was performed in 36 (83.7%) and emergency EVAR in 7 (16.3%). Technical success was achieved in 42 patients (100%) with no conversion to OAR. Stent-graft related complications were (21.0%) endoleaks, (2.3%) graft limb occlusion, (0%) graft infection, and (2.3%) rupture-EVAR. Systemic complications were (2.3%) myocardial infarction (MI), (2.3%) stroke, (2.3%) spinal cord injury (SCI), (2.3%) respiratory failure, (19.0%) wound complications, and (2.3%) acute lower limb ischemia (ALI). The 30-day mortality was (2.3%) due to perioperative MI and the late graft related mortality was (2.3%) due to rupture-EVAR.
UNASSIGNED: EVAR showed a high technical success rate with no conversion to OAR. The most common complications were type II and type I endoleaks followed by graft limb occlusion. The 30-day mortality was 2.3% due to perioperative MI. Only one late stent-graft related mortality was registered due to rupture-EVAR.
UNASSIGNED: Patients with infra-renal AAA treated by elective and emergency EVAR between March 2014 and November 2020 were retrospectively identified. Demographic data, risk factors, American Society of Anesthesiologists (ASA) score, systemic complications, stent-graft related complications, surgical site complications, 30-day mortality, late EVAR related mortality, estimated blood loss, intensive care unit (ICU) length of stay (LOS), hospital LOS and follow-up durations were collected and analyzed.
UNASSIGNED: A total of 43 patients underwent EVAR during the period of study. There were 42 males (97.7%) and 1 female (2.3%). The mean age was 68.8 ± 6.2 years. Elective EVAR was performed in 36 (83.7%) and emergency EVAR in 7 (16.3%). Technical success was achieved in 42 patients (100%) with no conversion to OAR. Stent-graft related complications were (21.0%) endoleaks, (2.3%) graft limb occlusion, (0%) graft infection, and (2.3%) rupture-EVAR. Systemic complications were (2.3%) myocardial infarction (MI), (2.3%) stroke, (2.3%) spinal cord injury (SCI), (2.3%) respiratory failure, (19.0%) wound complications, and (2.3%) acute lower limb ischemia (ALI). The 30-day mortality was (2.3%) due to perioperative MI and the late graft related mortality was (2.3%) due to rupture-EVAR.
UNASSIGNED: EVAR showed a high technical success rate with no conversion to OAR. The most common complications were type II and type I endoleaks followed by graft limb occlusion. The 30-day mortality was 2.3% due to perioperative MI. Only one late stent-graft related mortality was registered due to rupture-EVAR.
摘要：
■在治疗肾下腹主动脉瘤（AAA）方面，腔内主动脉修复（EVAR）的侵入性明显小于开放主动脉修复（OAR）。然而,它并非没有可能导致严重发病率甚至死亡率的并发症。这项研究的目的是分享我们在与EVAR相关的支架移植物相关和全身并发症方面的单中心经验。
■对2014年3月至2020年11月期间接受择期和急诊EVAR治疗的肾下AAA患者进行回顾性鉴定。人口统计数据,危险因素，美国麻醉医师协会（ASA）评分，全身性并发症,支架移植物相关并发症,手术部位并发症,30天死亡率，晚期EVAR相关死亡率，估计失血量,重症监护病房（ICU）住院时间（LOS），收集并分析医院LOS和随访时间.
■在研究期间共有43名患者接受了EVAR。男性42例（97.7%），女性1例（2.3%）。平均年龄为68.8±6.2岁。选择性EVAR36例（83.7%），急诊EVAR7例（16.3%）。42例患者（100％）获得了技术成功，没有转换为OAR。支架移植物相关并发症为内漏（21.0%），（2.3%）移植肢体闭塞，（0％）移植物感染，和（2.3%）破裂-EVAR。全身并发症（2.3％）心肌梗死（MI），(2.3%)中风,（2.3％）脊髓损伤（SCI），（2.3%）呼吸衰竭，（19.0%）伤口并发症，(2.3%)急性下肢缺血(ALI)。围手术期MI导致30天死亡率（2.3％），破裂EVAR导致晚期移植物相关死亡率（2.3％）。
■EVAR显示出很高的技术成功率，没有转换为OAR。最常见的并发症是II型和I型内漏，其次是移植肢闭塞。围手术期MI导致30天死亡率为2.3%。由于破裂-EVAR，仅记录了一例晚期支架移植物相关死亡。
■对2014年3月至2020年11月期间接受择期和急诊EVAR治疗的肾下AAA患者进行回顾性鉴定。人口统计数据,危险因素，美国麻醉医师协会（ASA）评分，全身性并发症,支架移植物相关并发症,手术部位并发症,30天死亡率，晚期EVAR相关死亡率，估计失血量,重症监护病房（ICU）住院时间（LOS），收集并分析医院LOS和随访时间.
■在研究期间共有43名患者接受了EVAR。男性42例（97.7%），女性1例（2.3%）。平均年龄为68.8±6.2岁。选择性EVAR36例（83.7%），急诊EVAR7例（16.3%）。42例患者（100％）获得了技术成功，没有转换为OAR。支架移植物相关并发症为内漏（21.0%），（2.3%）移植肢体闭塞，（0％）移植物感染，和（2.3%）破裂-EVAR。全身并发症（2.3％）心肌梗死（MI），(2.3%)中风,（2.3％）脊髓损伤（SCI），（2.3%）呼吸衰竭，（19.0%）伤口并发症，(2.3%)急性下肢缺血(ALI)。围手术期MI导致30天死亡率（2.3％），破裂EVAR导致晚期移植物相关死亡率（2.3％）。
■EVAR显示出很高的技术成功率，没有转换为OAR。最常见的并发症是II型和I型内漏，其次是移植肢闭塞。围手术期MI导致30天死亡率为2.3%。由于破裂-EVAR，仅记录了一例晚期支架移植物相关死亡。
